Rich Pharmaceuticals Inc., of Beverly Hills, Calif., said it filed its submission package to the institutional review board of Phramongkutklao Hospital in Bangkok, Thailand, as part of a process that will lead to a study for the treatment of acute myelocytic leukemia in refractory patients in a phase I/II trial. Read More
Savara Inc., of Austin, Texas, closed an underwritten public offering of about 9 million shares of its common stock at a price to the public of $4.75 per share, which included 613,157 shares upon the partial exercise of the underwriters' option to purchase additional shares of Savara common stock at the public offering price, less the underwriting discounts and commissions. Read More
PolarityTE Inc., a Salt Lake City-based regenerative medicine and tissue engineering company, has reported preclinical results demonstrating that its lead candidate, SkinTE, regenerated full-thickness, organized skin and hair follicles in third-degree burn wounds. Read More
SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med), of Shanghai, presented at the recent American Society of Clinical Oncology meeting in Chicago full phase III data for fruquintinib, an oral VEGF inhibitor, for third-line colorectal cancer (CRC). Read More
Thursday's hearing of the Senate Finance Committee addressing the fiscal 2018 budget did not lack for fireworks, although much of the controversy centered around Medicaid funding and related work on the opioid crisis. Durable medical equipment (DME) may fare well going forward as Health and Human Services Secretary Tom Price vowed that the DME bidding program is up for review, but federal funding for Zika could suffer if proposed cuts to the CDC budget go through as proposed. Read More
DUBLIN – Eli Lilly and Co. is paying Keybioscience AG $55 million up front and is also on the hook for potential milestone payments arising from an alliance focused on a new drug class, dubbed dual amylin calcitonin receptor agonists (Darcas), in development for diabetes and other metabolic diseases. Read More
Shares of Newlink Genetics Corp. were dented 12.4 percent on Monday after the company reported a failed phase II experiment with lead program indoximod, in combination with taxane chemotherapy, for patients with metastatic breast cancer, based on top-line data. Read More
2X Oncology Inc., of Cambridge, Mass., said it obtained the investigational new drug application for 2X-111 (doxorubicin hydrochloride and glutathione, formerly 2B3-101) from 2-BBB Medicines BV, of Leiden, the Netherlands, and assumed full ownership and future development of the candidate to treat brain metastases from breast cancer and recurrent glioblastoma multiforme. Read More
